United Therapeutics (UTHR) Fundamental Analysis: Revenue, Earnings & Valuation

6.43 / 10

Outperform

Fundamental analysis rates UTHR Outperform with a 6.4/10 score. Strengths include high Fixed‑asset and Inventory turnover, and robust Asset‑MV, Profit‑MV, Cash‑MV ratios. Caution arises from weak Revenue‑MV, Current‑asset turnover and low gross margin, yet overall fundamentals remain solid.

Analysis Checks(7/10)

Revenue-MV

Value-0.90

Score1/3

Weight10.85%

1M Return5.44%

Inventory turnover ratio

Value2.25

Score2/3

Weight-0.80%

1M Return-0.56%

Gross profit margin (%)

Value87.92

Score0/3

Weight-6.31%

1M Return-5.42%

Profit-MV

Value1.16

Score3/3

Weight24.29%

1M Return9.40%

Income tax / Total profit (%)

Value22.13

Score3/3

Weight4.36%

1M Return2.26%

Current assets turnover ratio

Value0.84

Score1/3

Weight-0.27%

1M Return-0.17%

Fixed assets turnover ratio

Value2.16

Score2/3

Weight0.01%

1M Return0.01%

Cost of sales ratio (%)

Value12.08

Score2/3

Weight-5.08%

1M Return-3.62%

Asset-MV

Value-0.55

Score2/3

Weight30.26%

1M Return13.10%

Cash-MV

Value-0.26

Score3/3

Weight42.69%

1M Return15.07%

Is UTHR undervalued or overvalued?

UTHR scores 6.43/10 on fundamentals and holds a Discounted valuation at present. Backed by its 19.71% ROE, 41.94% net margin, 17.46 P/E ratio, 3.28 P/B ratio, and 13.96% earnings growth, these metrics solidify its Outperform investment rating.